May 9, 2017 08:22 AM EDT
Bioregnum
Opinion

Af­ter Kite Phar­ma stuns an­a­lysts with news of a death in lead CAR-T study, safe­ty ques­tions sour launch fore­cast

There may nev­er have been a right way for Kite Phar­ma …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

J&J, Pro­tag­o­nist re­veal two Phase 3 wins for oral IL-23 drug that's ex­pect­ed to be a block­buster

For­mer NCI di­rec­tor teams up with se­r­i­al en­tre­pre­neur for $70M VC fund tar­get­ing 'su­per-ear­ly' sci­ence

Bris­tol My­ers takes on au­toim­mune dis­eases with cell ther­a­py, plus new da­ta from Ca­balet­ta and Kyver­na

Bio­gen, UCB de­tail re­sponse rates in Phase 3 lu­pus tri­al af­ter sur­pris­ing suc­cess

Mer­ck fi­nal­ly has sub­cu­ta­neous Keytru­da re­sults, and it's go­ing to reg­u­la­tors

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times